|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Predictors of kidney tubular dysfunction induced by adefovir treatment for chronic hepatitis B显示文摘AIM:To investigate the predictors of proximal kidney tubular dysfunction(PKTD)induced by adefovir dipivoxil(ADV)treatment for chronic hepatitis B.METHODS:Seventy-nine patients(age at the evaluation of PKTD:56.9±10.7 years)with chronic hepatitis B undergoing long-term oral antiviral nucleos(t)ide analogue treatment were consecutively recruited.PKTD was defined by the presence of at least two of the following five abnormalities:phosphate diabetes,nondiabetic glucosuria,metabolic acidosis,β2-microglobulinuria,or renal hypouricemia.The single-nucleotide polymorphisms(SNPs)in the SLC22A6 gene encoding human organic anion transporter 1(h OAT1)and ABCC2 encoding multidrug resistance protein 2(MRP2)were analyzed using the Taq Man Allelic Discrimination Demonstration Kit.RESULTS:Nine(30.0%)of the 30 ADV-treated patients were diagnosed with PKTD,while no patients without ADV developed PKTD(P<0.001).Three patients with ADV were diagnosed with symptomatic osteomalacia.Among the patients who took ADV,those with PKTD were of higher age at initiation,had significantly longer treatment duration,and had a significantly lower body mass index than those without PKTD.The incidence of PKTD dramatically increased after 96 mo from the start of ADV administration.In contrast,the SNPs were not correlated with PKTD.Logistic regression analysis extracted older age at initiation(OR=5.0,95%CI:1.1-23.4;P=0.040)and longer treatment duration(OR=3.2,95%CI:1.2-8.6;P=0.020)as significant factors associated with PKTD.CONCLUSION:Our results suggest that the tubular function of the kidney of older patients undergoing longterm ADV treatment should be carefully evaluated. | Motohiro Shimizu Norihiro Furusyo Hiroaki Ikezaki Eiichi Ogawa Takeo Hayashi Takeshi Ihara Yuji Harada Kazuhiro Toyoda Masayuki Murata Jun Hayashi | 2015 | World Journal of Gastroenterology2015，21，7： | 18 |
| 2 | Interferon alpha plus ribavirin combination treatment of Japanese chronic hepatitis C patients with HCV genotype 2:A project of the Kyushu University Liver Disease Study Group显示文摘瞄准:决定一座干扰素高山的功效哈并且为感染遗传型 2 的丙肝病毒(HCV ) 的日本病人的 ribavirin 联合治疗,多中心研究回顾地被分析。方法:总共,有 HCV 遗传型 2 的 173 个病人每天一个星期和 ribavirin 的 600-800 mg 为 24 wk 三次皮下地收到 interferon-alpha。结果:总的来说持续的 virological 反应(SVR ) ,在浆液的定义同样无法发现的 HCV RNA,在治疗的结束以后的 24 wk,在 84.4% 显著地高,(146/173 ) 由 intention-to-treat 分析。在 SVR 的有效差量有或没有 ribavirin (46.9% 对 92.9%) 的中止在病人之间被发现,但是没有差别有或没有 ribavirin 的剂量减小在那些之间被发现。在 SVR 的有效差量也与 16 或更与不到 16 wk 和病人在病人之间被发现 ribavirin 治疗(34.8% 对 92.0%) 的星期。结论:24-wk 干扰素和 ribavirin 治疗为有 HCV 遗传型 2 的日本病人是高度有效的。SVR 的重要预言者是 ribavirin 治疗的继续多达 16 个星期。 | Norihiro Furusyo Masaki Katoh Yuichi Tanabe Eiji Kajiwara Toshihiro Maruyama Junya Shimono Hironori Sakai Makoto Nakamuta Hideyuki Nomura Akihide Masumoto Shinji Shimoda Kazuhiro Takahashi Koichi Azuma Jun Hayashi Kyushu University Liver Disease Study Group | 2006 | World Journal of Gastroenterology2006，12，5： | 8 |
| 3 | Efficacy of pegylated interferon alpha-2b and ribavirin treatment on the risk of hepatocellular carcinoma in patients with chronic hepatitis C: A prospective, multicenter study显示文摘 | Eiichi Ogawa Norihiro Furusyo Eiji Kajiwara Kazuhiro Takahashi Hideyuki Nomura Toshihiro Maruyama Yuichi Tanabe Takeaki Satoh Makoto Nakamuta Kazuhiro Kotoh Koichi Azuma Kazufumi Dohmen Shinji Shimoda Jun Hayashi | 2012 | Journal of Hepatology2012，，： | 3 |
| 4 | Long-term effects of lamivudine treatment in Japanese chronic hepatitis B patients显示文摘AIM:To analyze the association between the emergence of tyrosine-methionine-asparatate-asparatate(YMDD) mutants(reverse transcription;rtM204I/V) and deterioration of liver function during long-term lamivudine treatment of Japanese patients with chronic hepatitis B virus(HBV) infection.METHODS:The data of 61 consecutive Japanese patients with chronic hepatitis B who underwent continuous lamivudine treatment for more than 24 mo and had a virological response were analyzed.Analysis of YMDD mutants was done by real-time polymerase chain reaction with LightCycler probe hybridization assay for up to 90 mo(mean,50.8 mo;range,24-90 mo).RESULTS:A mixed mutant-type(YMDD + tyrosine-isoleucine-asparatate-asparatate:YIDD or tyrosine-valineasparatate-asparatate:YVDD) or a mutant-type(YIDD or YVDD) were found in 57.4% of 61 patients at 1 year,78.7% of 61 patients at 2 years,79.6% of 49 patients at 3 years,70.5% of 34 patients at 4 years,68.4% of 19 patients at 5 years,57.1% of 14 patients at 6 years,and 33.3% of 6 patients at 7 years.Of the 61 patients,56(92%) had mixed mutant-or a mutant-type.Only 5(8%) had no mutants at each observation point.Virological breakthrough was found in 26(46.4%) of 56 patients with YMDD mutants,20 of whom had a hepatitis flare-up:the remaining 30(53.6%) had neither a virological breakthrough nor a flare-up.All 20 patients who developed a hepatitis flare-up had a biochemical and virological response after adefovir was added to the lamivudine treatment.CONCLUSION:Our results suggest that it is possible to continue lamivudine treatment,even after the emergence of YMDD mutants,up to the time that the patients develop a hepatitis flare-up. | Masayuki Murata Norihiro Furusyo Mami Unno Eiichi Ogawa Kazuhiro Toyoda Hiroaki Taniai Hachiro Ohnishi Jun Hayashi | 2011 | World Journal of Gastroenterology2011，17，24： | 3 |
| 5 | The longitudinal quantitative assessment by transient elastography of chronic hepatitis C patients treated with pegylated interferon alpha-2b and ribavirin显示文摘 | Eiichi Ogawa Norihiro Furusyo Kazuhiro Toyoda Hiroaki Takeoka Shinji Maeda Jun Hayashi | 2009 | Antiviral Research2009，，2： | 2 |
| 6 | Telaprevir can be successfully and safely used to treat older patients with genotype 1b chronic hepatitis C显示文摘 | Norihiro Furusyo Eiichi Ogawa Makoto Nakamuta Eiji Kajiwara Hideyuki Nomura Kazufumi Dohmen Kazuhiro Takahashi Takeaki Satoh Koichi Azuma Akira Kawano Yuichi Tanabe Kazuhiro Kotoh Shinji Shimoda Jun Hayashi | 2013 | Journal of Hepatology2013，，2： | 2 |
| 7 | Pre-treatment role of inosine triphosphate pyrophosphatase polymorphism for predicting anemia in Egyptian hepatitis C virus patients显示文摘AIM: To investigate and clarify, for the first time, the role of inosine triphosphate pyrophosphatase (ITPA ) polymorphism in Egyptian chronic hepatitis C virus (HCV) patients.METHODS:The human genomic DNA of all patients was extracted from peripheral blood cells in order to determine the single nucleotide polymorphism (SNP) of ITPA (rs1127354). SNP genotyping was performed by real time polymerase chain reaction (PCR, ABI TaqMan allelic discrimination kit) for 102 treatment-naive Egyptian patients with chronic HCV. All patients had no evidence of cardiovascular or renal diseases. They received a combination treatment of pegylated interferon α (PEG-IFNα) as a weekly subcutaneous dose plus an oral weight-adjusted dose of ribavirin (RBV). The majority received PEG-IFNα2a (70.6%) while 29.4% received PEG-IFNα2b. The planned duration of treatment was 24-48 wk according to the viral kinetics throughout the course of treatment. Pre-treatment liver biopsy was done for each patient for evaluation of fibrosis stage and liver disease activity. The basal viral load level was detected quantitatively by real time PCR while viral load throughout the treatment course was performed qualitatively by COBAS TaqMan assay. RESULTS: Ninety-three patients (91.2%) had ITPA SNP CC genotype and 9 (8.8%) had non-CC genotype (CA and AA). The percentage of hemoglobin (Hb) decline was higher for CC patients than for non-CC patients, particularly at weeks 4 and 8 (P=0.047 and 0.034, respectively). During the first 12 wk of treatment, CC patients had significantly more Hb decline > 3 g/dL than non-CC patients: 64.5% vs 22.2% at weeks 8 and 12, respectively, (P=0.024 and 0.038). Reduction of the amount of the planned RBV dose was significantly higher for CC patients than non-CC patients during the first 12 wk (18% ± 12.1% vs 8.5% ± 10.2%, P=0.021). The percentage of CC patients with RBV dose reduction was significantly greater than that of non-CC patients (77.4% vs 44.4%, P=0.044). Multivariate analysis identified only the percentage of RBV dose as a predictor for Hb decline. Platelet decline was significantly higher in non-CC patients than CC patients at weeks 12, 24 and 48 (P=0.018, 0.009 and 0.026, respectively). CONCLUSION: Rs1127354 ITPA polymorphism plays a decisive role in protecting against treatment-induced anemia and the need for RBV dose reduction in Egyptian HCV patients. | Walaa H Ahmed Norihiro Furusyo Saad Zaky Abeer Sharaf Eldin Hany Aboalam Eiichi Ogawa Masayuki Murata Jun Hayashi | 2013 | World Journal of Gastroenterology2013，19，9： | 2 |
| 8 | Thymus and activation regulated chemokines in children with atopic dermatitis:Kyushu University Ishigaki Atopic Dermatitis Study (KIDS) 显示文摘 | Furusyo N Takeoka H Toyoda K | 2007 | Eur J Dermatol2007，17，5： | 1 |
| 9 | The elimination of hepatitisB virus infection:changing seroep idemiology of hepatitis A and B virus infection in Okinawa Japan over a26-year period显示文摘 | N Furusyo J Hayashi Y Sawayama | 1998 | American Society of Tropical Medicine and Hygiene1998，59，5： | 1 |
| 10 | The elimination of hepatitis B virus infection:changing seroepidemiology of hepatitis A and B virus infection in Okinawa Japan Over A26-year period显示文摘 | Norihiro Furusyo Jun Hayashi Yasunori Sawayama | 1998 | Am J Med Hyp1998，59，5： | 1 |
| 11 | Clinical milestones for the prediction of severe anemia by chronic hepatitis C patients receiving telaprevir-based triple therapy显示文摘 | Eiichi Ogawa Norihiro Furusyo Makoto Nakamuta Eiji Kajiwara Hideyuki Nomura Kazufumi Dohmen Kazuhiro Takahashi Takeaki Satoh Koichi Azuma Akira Kawano Yuichi Tanabe Kazuhiro Kotoh Shinji Shimoda Jun Hayashi | 2013 | Journal of Hepatology2013，，： | 1 |
| 12 | Transient elastography for patients with chronic hepatitis B and C virus infection: Non-inva- sive, quantitative assessment of liver fibrosis显示文摘 | Ogawa E Furusyo N Toyoda K | 2007 | Hepatol Res2007，37，12： | 1 |
| 13 | Effect on carotid atherosclerosis of probucol plus levofloxacin for Chlamydia pneumoniae infection显示文摘 | Yasunori Sawayama Masafumi Tatsukawa Kensuke Kikuchi Shinji Maeda Hachiro Ohnishi Norihiro Furusyo Jun Hayashi | 2007 | Journal of Infection and Chemotherapy2007，，2： | 1 |
| 14 | Longitudinal as- sessment of liver stiffness by transient elastography for chronic hepatitis B patients treated with nucleoside analog 显示文摘 | Ogawa E Furusyo N Murata M etal | 2011 | HepatolRes2011，41，12： | 1 |
| 15 | Double point mutation in the core promoter region of hepatitis B virus genotype C may be related to liver deterioration in patients with chronic HBV infection显示文摘 | Nakashima H Furusyo N Kubo N | 2004 | Gastroenterol Hepatol2004，19，5： | 1 |
| 16 | Clinical outcomes of hepatitis B virus (HBV) genotypes B and C in Japanese patients with chronic HBV infection显示文摘 | Furusyo N Nakashima H Kashiwagi K | 2002 | Am J Trop Med Hyg2002，67，2： | 1 |
| 17 | Inhibitory effects of orally administrated liposomal bovine lactoferrin on the LPS-induced osteoclastogenesis显示文摘 | Yamano E Miyauchi M Furusyo H | 2010 | Laboratory Invest2010，98，8： | 1 |
| 18 | High molecular weight form of adiponectin levels of Japanese patients with chronic hepatitis C virus infection显示文摘 | FURUSYO N SAWAYAMA Y MAEDA S | 2007 | Hepatol Res2007，37，： | 1 |
| 19 | A case of granulomatosis with polyangiitis preceded by subacute thyroiditis显示文摘 | Mukae H Furusyo N Murata M | 2015 | Clin Case Rep2015，3，3： | 1 |
| 20 | Plasma glycated albumin level and atherosclerosis: results from the Kyushu and Okinawa Population Study (KOPS) 显示文摘 | Furusyo N Koga T Ai M | 2013 | Int J Cardiol2013，167，5： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员